个人简历

石虎兵，教授、博士生导师，2001年毕业于吉林大学，获本科、硕士学位；2007年毕业于清华大学，获得博士学位；后在美国加州大学洛杉矶分校从事肿瘤分子靶向治疗及耐药性机理研究。研究期间共发表研究论文20篇，影响因子共计358.2，被引用3020次，撰写专著1项，以第一作者或共同第一作者身份共发表论文9篇，包括：Nature（1篇），Cell （1篇），Cancer Cell （1篇），Nature Communications（1篇），Cancer Discovery（3篇，影响因子19.5），Blood（1篇，国内发表、封面文章），Cancer Research（1篇），影响因子共计186.8，被引用1855次。

研究领域

"""""1. 精准个体化治疗\r
2. 肿瘤分子靶向治疗\r
3. 肿瘤免疫治疗\r
4. 生物信息学、数据分析"

近期论文

Lunxi Liang, Huanbin Wang, Hubing Shi, Zhaoli Li, Han Yao, Zhigao Bu, Ningning Song, Chushu Li, Dabin Xiang, Yao Zhang, Jilin Wang, Ye Hu, Qi Xu, Yanlei Ma, Zhongyi Cheng, Yingchao Wang, Shuliang Zhao, Jin Qian, Yingxuan Chen, Jing-Yuan Fang, Jie Xu. (2018) A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity. Cell Chem Biol. 2018 Jun 21;25(6):761-774.\r
\r
Huanbin Wang, Han Yao, Chushu Li, Hubing Shi, Jiang Lan, Zhaoli Li, Yao Zhang, Lunxi Liang, Jing-Yuan Fang & Jie Xu (2019) HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 15(1):42-50.\r
\r
Han Yao*, Jiang Lan*, Chushu Li*, Hubing Shi*, Jean-Philippe Brosseau, Huanbin Wang, Haojie Lu, Caiyun Fang, Yao Zhang, Lunxi Liang, Yu Xue & Jie Xu (2019) Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat. Biomed. Eng. 3(4):306-317.\r
\r
Xiaowei Liu*, Yanlin Feng*, Guangchao Xu*, Yang Chen*, Ya Luo, Jinen Song, Yu Bao, Jiqiao Yang, Chune Yu, Yanna Li, Haoyu Ye, Bowen Ke, Bo Chen, Jianping Hu, Jie Xu, Huan Meng, Haiyuan Zhang#, and Hubing Shi# (2019) MAPK-Targeted Drug Delivered by a pH Sensitive MSNP Nanocarrier Synergizes with PD-1 Blockade in Melanoma without T-cell Suppression. Adv. Funct. Mater. 12(29):1806916.\r
\r
Xin Sun, Li Liang, Jinke Gu, Wei Zhuo, Xiao Yan, Tao Xie, Zhixiang Wu, Xinyu Liu, Xiaojun Gou, Wei Liu, Gang He, Ya Gan, Shan Chang, Hubing Shi# & Jianping Hu# (2019) Inhibition of programmed cell death protein ligand-1 (PD-L1) by benzyl ether derivatives: analyses of conformational change, molecular recognition and binding free energy. J Biomol Struct Dyn. 37(18):4801-4812.\r
\r
Wei Liu, Jie Li, Ping Zhang, Qiaoyun Hou, Shi Feng, Lisheng Liu, Dawei Cui, Hubing Shi, Yan Fu, and Yongzhang Luo (2019) A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic. Cancer Sci. 110(9):2941-2959.\r
\r
Tao Xie*, Zhixiang Wu*, Jinke Gu, Runyu Guo, Xiao Yan, Huaichuan Duan, Xinyu Liu, Wei Liu, Li Liang, Hua Wan, Yafei Luo, Dianyong Tang, Hubing Shi# and Jianping Hu# (2019) The global motion affecting electron transfer in Plasmodium falciparum type II NADH dehydrogenases: a novel non-competitive mechanism for quinoline ketone derivative inhibitors. Phys Chem Chem Phys. 21(33):18105-18118.\r
\r
Wei Vivian Li*, Shan Li*, Xin Tong, Ling Deng, Hubing Shi#, and Jingyi Jessica Li# (2019) AIDE: annotation-assisted isoform discovery with high precision. Genome Res. 29(12):2056-2072.\r
\r
Xinyu Liu, Yiwen Zhang, Huaichuan Duan, Qing Luo, Wei Liu, Li Liang, Hua Wan, Shan Chang, Jianping Hu, and Hubing Shi1# (2020) Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations. Front Mol Biosci. 6:164.\r
\r
Ke Jiang, Genpeng Li, Wenjie Chen, Linlin Song, Tao Wei, Zhihui Li, Rixiang Gong, Jianyong Lei, Hubing Shi#, and Jingqiang Zhu# (2020) Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas. Onco Targets Ther. 13:1311-1319.\r
\r
Xiao Yan, Yafei Luo, Wei Liu, Li Liang, Ya Gan, Zhongzhu Chen, Zhigang Xu, Hua Wan, Dianyong Tang, Hubing Shi# and Jianping Hu# (2020) Strategy used to synthesize high activity and low Pd catalyst for Suzuki coupling reaction: an experimental and theoretical investigation. Phys Chem Chem Phys. 22(11):6222-6230.\r
\r
Zhixiang Wu, Lianxin Peng, Yichen Hu, Tao Xie, Hailian Yan, Hua Wan, Wei Liu, Li Liang, Zhenjian Xie, Kunping Liu, Hubing Shi#, Gang Zhao#, Jianping Hu# (2020) BP[dG]-induced distortions to DNA polymerase and DNA duplex: A detailed mechanism of BP adducts blocking replication. Food Chem Toxicol. 140:111325\r
\r
Chune Yu, Min Zhang, Jinen Song, Xiaobo Zheng, Guangchao Xu, Yu Bao, Jiang Lan, Dan Luo, Jianping Hu, Jingyi Jessica Li and Hubing Shi* (2020) Integrin-Src-YAP1 signaling mediates the melanoma acquired resistance to MAPK and PI3K/mTOR dual targeted therapy. Molecular Biomedicine, 1:12.\r
\r
Xiaowei Liu*, Yanlin Feng*, Jie Xu*, Ying Shi, Jiqiao Yang, Rongjie Zhang, Jinen Song, Xin Bai, Xi Wu, Yu Bao, Ya Luo, Huifang Li, Li Chai, Changyang Gong, Yan Wang, Bo Chen, Jianping Hu, Yan Fu, Yongzhang Luo, Haiyuan Zhang#, Hubing Shi#. (2021) Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade. J Control. Release. 332:194-209.\r
\r
Guangchao Xu*, Ya Luo*, Wenshuang Wu*, Xiaowei Liu*, Xin Yu, Yu Bao, Xiujing He, Jing Yu, Yanna Li, Jiqiao Yang, Rongjie Zhang, Chune Yu, Hongying Chen, Jie Xu, Jianping Hu, Jing Jing, Hubing Shi (2022) The evolution of acquired resistance to BRAF inhibitor is sustained by IGF1-driven tumor vascular remodeling. J Invest Dermatol. 142(2):445-458.\r
\r
Qing Luo, Huaichuan Duan, Hailian Yan, Xinyu Liu, Lianxin Peng, Yichen Hu, Wei Liu, Li Liang, Hubing Shi#, Gang Zhao#, Jianping Hu# (2020) Specifically targeting Mtb cell-wall and TMM transporter: the development of MmpL3 inhibitors. Curr Protein Pept Sci. Online ahead of print.\r
\r
Chune Yu*, Dan Luo*, Jing Yu*, Min Zhang, Xiaobo Zheng, Guangchao Xu, Jiaxin Wang, Huiling Wang, Yufei Xu, Ke Jiang, Jie Xu, Xuelei Ma, Jing Jing#, Hubing Shi# (2021) Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Oncogene. 41(2):191-203.\r
\r
Xiujing He, Jing Yu, and Hubing Shi (2021) Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated with Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Front. Pharmacol., 12:797852.\r
\r
Xin Bai, Xueyan Wang, Guozhen Ma, Jinen Song, Xiaowei Liu, Xi Wu, Yujie Zhao, Xu Liu, Zhihui Liu, Wei Zhang, Xin Zhao, Zirui Zheng, Jing Jing#, and Hubing Shi# (2021) Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. Front Immunol. 12:793831.\r
\r
Xiaobo Zheng*, Jinen Song*, Chune Yu*, Zongguang Zhou*, Xiaowei Liu, Jing Yu, Guangchao Xu, Jiqiao Yang, Xiujing He, Xin Bai, Ya Luo, Yu Bao, Huifang Li, Lie Yang, Mingqing Xu, Nan Song, Xiaodong Su, Jie Xu, Xuelei Ma#, and Hubing Shi# (2022) Single-cell transcriptomic profiling unravels the adenoma-initiation role of protein tyrosine kinases during colorectal tumorigenesis. Signal Transduct Target Ther. ;7(1):60.